欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2007, Vol. 12 ›› Issue (4): 465-469.

• 临床药理学 • 上一篇    下一篇

两种剂量的吡嘧司特钾片临床研究报告

徐勤娥1, 林子萍1, 李泽卿2, 余盈盈3, 马未央4, 岳志勇5, 史丽6, 薛卫国7, 赵俊1, 柴怡1, 于浩8, 张银娣8, 沈建平8   

  1. 1南京医科大学第一附属医院药研机构及五官科;2南京军区南京总医院五官科, 南京210002, 江苏;
    3浙江大学医学院附属第一医院五官科;4浙江大学医学院附属第二医院五官科, 杭州310000, 浙江;
    5山东省立医院五官科;6山东大学齐鲁医院五官科, 济南250000, 山东;
    7青岛市市立医院五官科, 青岛266000, 山东;
    8南京医科大学, 南京210029, 江苏
  • 收稿日期:2006-06-20 修回日期:2006-06-20 发布日期:2020-10-30

Clinical trial report of two doses of pemirolast potassium

XU Qin-e1, LIN Zi-ping1, LI Ze-qing2, YU Ying-ying3, MA Wei-yang4, YUE Zhi-yong5, SHI Li6, XUE Wei-guo7, ZHAO Jun1, CHAI Yi1, YU Hao8, ZHANG Yin-di8, SHEN Jian-ping8   

  1. 1Drug Research Agency and Department of Otorhinolaryngology, The First Affiliated Hospital of Nanjing Medical University, 2Department of Otorhinolaryngology, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, Jiangsu, China;
    3Department of Otorhinolaryngology, Zhejiang First Hospital, 4Department of Otorhinolaryngology, Second Affiliated Hospital of ZhejiangUniversity College of Medicine, Hangzhou 310000, Zhejiang, China;
    5Department of Otorhinolaryngology, Shandong Provincial Hospital, 6Department of Otorhinolaryngology, Qilu Hospital, Jinan 250000, Shandong, China;
    7Department of Otorhinolaryngology, Qingdao Hospital, Qingdao 266000, Shandong, China;
    8Nanjing Medical University, Nanjing 210029, Jiangsu, China
  • Received:2006-06-20 Revised:2006-06-20 Published:2020-10-30

摘要: 目的 以曲尼司特片100 mg 为对照, 分别评价两个单位研制的吡嘧司特钾片5 mg (NTFM 药业有限公司, 试验1) 、10 mg (QDGFGKJ 药业股份有限公司, 试验2) 治疗过敏性鼻炎的临床安全性和有效性。单剂量口服10 mg 吡嘧司特钾片测定血药浓度经时过程, 并估算主要药代动力学参数。 方法 试验1 、试验2 的试验组每日2 次在早晚饭后分别口服吡嘧司特钾片5 mg 或10 mg, 对照组均为在早晚饭后分别口服曲尼司特片100 mg, 疗程均为4 周。试验3 为20 名男性志愿受试者单剂量口服吡嘧司特钾1片(10 mg 片) 。 结果 有效性:试验1 结果显示, 试验药吡嘧司特钾片5 mg 与对照药曲尼司特片100 mg 用于过敏性鼻炎治疗后症状积分疗效、总体疗效两组之间比较差异均有统计学意义(P<0.01), 说明试验药吡嘧司特钾片5 mg 改善过敏性鼻炎症状积分的疗效、总体疗效均优于对照药曲尼司特片100 mg 。试验2 结果显示, 试验药吡嘧司特钾片10 mg 与对照药曲尼司特片100 mg 用于过敏性鼻炎病人治疗后症状积分疗效、总体疗效两组之间比较差异均无统计学意义(P >0.05), 说明试验药吡嘧司特钾片10 mg 改善过敏性鼻炎症状积分的疗效、总体疗效均与对照药曲尼司特片100 mg 相似。安全性:试验1 结果显示, 试验药吡嘧司特钾片5 mg 与对照药曲尼司特片100 mg 用于过敏性鼻炎的受试者不良反应发生率分别为4.81 %、3.21 %,两组之间比较差异无统计学意义(P >0.05), 且两组均未见发生严重不良反应。试验2 结果显示, 试验药吡嘧司特钾片10 mg 与对照药曲尼司特片100 mg 用于过敏性鼻炎的受试者不良反应发生率分别为2.94 %、10.00 %, 两组之间比较差异无统计学意义(P >0.05), 且两组均未见发生严重不良反应。试验3 为单剂量口服10 mg 吡嘧司特钾片测定血药浓度经时过程。 结论 吡嘧司特片治疗过敏性鼻炎5 mg 片 次、10 mg 片 次、每日2 次、疗程4 周,两种剂量给药均是安全、有效的。

关键词: 双模拟, 临控率, 吡嘧司特, 曲尼司特

Abstract: AIM: Using 100 mg tranilast as control, to investigate the clinical safety and effect of 5 mg or 10 mg pemirolast potassium which is for the treatment of allergic rhinitis. METHODS: Patients in the trial groups took pemirolast potassium 5 mg or 10 mg orally after breakfast and supper daily for 4 weeks.Patients in control group took tranilast 100 mg, and the usage and course of treatment were the same as trial groups.20 male volunteers took pemirolast potassium 10 mg once a day. RESULTS: Pemirolast potassium 5mg had a better effect for treatment of allergic rhinitis than tranilast 100 mg (P< 0.01).Pemirolast potassium 5 mg had a similar curative effect for allergic rhinitis to tranilast 100 mg.No serious drug reaction happened, and two doses of pemirolast potassium and tranilast 100 mg showed similar safety (P > 0.05). CONCLUSION: To cure allergic rhinitis, two doses of pemirolast potassium have good efficancy and safety compared to tranilast 100 mg.

Key words: double-simulate, rate of clinical control, pemirolast potassium, tranilast

中图分类号: